EXHIBIT 4.12 WATERGATE OFFICE LEASE 1. PARTIES: BASIC LEASE PROVISIONS; DEFINED TERMS 1.1 Parties. This Watergate Office Lease ("Lease") is entered into in the City of Emeryville, County of Alameda, State of California, between Spieker Properties,...Expansion Agreement • October 31st, 2003 • Geac Computer Corp LTD • Services-computer programming services
Execution Version EXPANSION AGREEMENT by and among Sprint Spectrum L.P., SprintCom, Inc. and Shenandoah Personal Communications, LLC dated as of February 1, 2018Expansion Agreement • May 5th, 2020 • Delaware
American Enterprise Park Morris Plains, New Jersey Immunomedics, Inc. FIFTH AMENDMENT Expansion AgreementExpansion Agreement • August 27th, 2009 • Immunomedics Inc • In vitro & in vivo diagnostic substances
This Fifth Amendment to Lease made as of this day of June 18, 2009 between WU/LH 300 American L.L.C., a Delaware limited liability company, having an office at c/o Lighthouse Real Estate Management, 60 Hempstead Avenue, Suite 718, West Hempstead, New York, 11552 (“Lessor”) and Immunomedics, Inc., having an office at 300 American Road, Morris Plains, New Jersey 07950 (“Lessee”).
AMENDMENT NUMBER 1 TO EXPANSION AGREEMENTExpansion Agreement • November 8th, 2010 • Amgen Inc • Biological products, (no disgnostic substances)
THIS AMENDMENT NUMBER 1 to the Expansion Agreement (the “Amendment”) is made and entered into as of the 10th day of September, 2010, by and between Glaxo Group Limited, registered in England as company number 305979, having its principal office at Glaxo Wellcome House, Berkley Avenue, Greenford, Middlesex, UB6 0NN, United Kingdom (“GSK”), and Amgen Inc., a Delaware corporation with a place of business at 1 Amgen Center Drive, Thousand Oaks, CA 91320 (“Amgen”).
HUAWEI DO BRASIL TELECOMUNICAÇÕES LTDA. EXPANSION AGREEMENT – 2005 Nº 78.294 / 78.295Expansion Agreement • April 30th, 2007 • Telemig Celular Participacoes Sa • Telephone communications (no radiotelephone)
TELEMIG CELULAR S.A., enrolled with the corporate taxpayers register (CNPJ/MF) under number 02.320.739/0001 -06, headquartered at Rua Levindo Lopes, 258, 8° andar, Funcionários, in the city of Belo Horizonte, State of Minas Gerais, Brazil, represented herein by its undersigned attorneys-in-fact, hereinafter referred to simply as TELEMIG and, jointly with AMAZÔNIA referred to jointly as PRINCIPAL; and, on the other hand,
EXPANSION AGREEMENTExpansion Agreement • October 16th, 2019 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • Texas
THIS EXPANSION AGREEMENT (this “Agreement”) dated as of October 15, 2019 (the “Effective Date”), is made and executed by TC LEGACY LAND VENTURE, LLC, a Delaware limited liability company (“Owner”), and REATA PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).
Note: Redacted portions have been marked with [*]. The redacted portions are subject to a request for confidential treatment that has been filed with the Securities and Exchange Commission. EXPANSION AGREEMENT BY AND BETWEEN AMGEN INC. AND GLAXO GROUP...Expansion Agreement • November 6th, 2009 • Amgen Inc • Biological products, (no disgnostic substances) • New York
This Expansion Agreement (this “Agreement”) is entered into as of the 27th day of July, 2009 (the “Effective Date”) by and between Amgen Inc., a Delaware corporation with a place of business at 1 Amgen Center Drive, Thousand Oaks, CA 91320 (“Amgen”), and Glaxo Group Limited, registered in England as company number 305979, doing business as “GlaxoSmithKline” and having its principal office at Glaxo Wellcome House, Berkley Avenue, Greenford, Middlesex, UB6 0NN, United Kingdom (“GSK”). Amgen and GSK are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
Amendment No. 2 to Expansion AgreementExpansion Agreement • February 27th, 2013 • Amgen Inc • Biological products, (no disgnostic substances) • New York
This amendment to the Expansion Agreement (this “Amendment”) is made and entered into as of the 24th day of January, 2012 (the “Execution Date”), by and between Amgen Inc., a Delaware corporation with a place of business at 1 Amgen Center Drive, Thousand Oaks, CA 91320 (“Amgen”), and Glaxo Group Limited, registered in England as company number 305979, doing business as “GlaxoSmithKline” and having its principal office at Glaxo Wellcome House, Berkley Avenue, Greenford, Middlesex, UB6 0NN, United Kingdom (“GSK”).
